ARK Genomic Revolution ETF (NY:ARKG)

48.72 +0.56 (+1.16%)

Official Closing Price Updated: 6:30 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ARK Genomic Revolution ETF

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock. ↗

October 18, 2026

Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, Oct. 12.

Via The Motley Fool

Topics ETFs

Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead? ↗

October 17, 2026

The gene-editing biotech stock is down more than 12% this year.

Via The Motley Fool

Topics ETFs Lawsuit

Cathie Wood's Ark Has Delivered Just a 13.8% Annualized Return Since 2014, Roughly Matching the S&P 500. Should You Trust Her Bold Predictions for 2030? ↗

September 06, 2026

Are her big ideas turning into big returns?

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise ↗

January 12, 2026

Via Stocktwits

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

August 31, 2026

Ark Invest was a buyer of tech stocks down as much as 53% from their recent all-time highs.

Via The Motley Fool

Topics ETFs

Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet. ↗

July 29, 2026

Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.

Via The Motley Fool

Topics ETFs Government

Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating ↗

July 22, 2026

This particular position isn't rooted solely in the science you've heard most about from the biopharma company so far.

Via The Motley Fool

Topics ETFs

Cathie Wood Just Bet Big on This Biotech Stock ↗

July 18, 2026

Ionis Pharmaceuticals' shares are down more than 27% so far this year. What does Cathie Wood see that others are missing?

Via The Motley Fool

Topics ETFs

Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock ↗

July 14, 2026

Cathie Wood's biotech ETF has largely moved on from the vaccine maker.

Via The Motley Fool

Topics ETFs

Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy? ↗

July 14, 2026

Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.

Via The Motley Fool

Topics Artificial Intelligence ETFs

Why Is CRSP Stock Falling Pre-Market Today? ↗

March 10, 2026

The company plans to issue $350 million in convertible senior notes that are scheduled to mature in 2031.

Via Stocktwits

RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ ↗

February 25, 2026

Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin.

Via Stocktwits

Topics Artificial Intelligence

CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial ↗

February 17, 2026

COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

Via Stocktwits

CMPS Stock Jumps 22% Pre-Market As Compass Sets Timeline For New Phase 3 Depression Trial Results ↗

February 17, 2026

The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

Via Stocktwits

TWST Shares Rise 8% — What’s Driving The Rally? ↗

February 02, 2026

Twist Bioscience Corporation hiked its fiscal year 2026 revenue guidance on the heels of a first quarter earnings report that beat Wall Street estimates.

Via Stocktwits

Topics Artificial Intelligence

Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD ↗

January 16, 2026

ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October.

Via Stocktwits

Topics Artificial Intelligence ETFs

Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50% ↗

November 30, 2025

This company's first product has started to generate revenue.

Via The Motley Fool

Topics ETFs

Why Tempus AI Stock Soared This Week ↗

November 28, 2025

A well-known analyst believes this AI healthcare stock has room to soar.

Via The Motley Fool

Topics Artificial Intelligence ETFs

Biotech ETFs Come Alive As Illumina Soars 23% — Is The Genomics Winter Finally Over? ↗

November 03, 2025

Illumina's 23% post-earnings rally revives optimism across biotech ETFs as investors bet on a genomics rebound and ex-China growth in 2025.

Via Benzinga

Topics ETFs

Wellgistics Health's 200% Surge Puts AI-Pharma Tie-Ups On The ETF Map ↗

October 24, 2025

Wellgistics Health (WGRX) soared 155% after a Datavault AI tie-up, stirring buzz around AI and healthcare ETFs.

Via Benzinga

Topics Artificial Intelligence ETFs

Wellgistics And DataVault Team Up To Transform Prescription Tracking ↗

October 22, 2025

DataVault AI and Wellgistics Health are collaborating to bring blockchain technology to the US prescription drug market.

Via Benzinga

Topics Artificial Intelligence

Trump's Weight-Loss Drug Push May Put These ETFs On A Diet ↗

October 17, 2025

Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure.

Via Benzinga

Topics ETFs Government

Nancy Pelosi, Cathie Wood Align On These 4 Stocks – Do You Own Any? ↗

October 10, 2025

Shared stocks between Nancy Pelosi and Cathie Wood include Alphabet, Amazon, NVIDIA, and Tempus AI. They also both own stakes in private company Databricks.

Via Benzinga

Topics Artificial Intelligence

Nancy Pelosi's Tempus Play Might Be Smartest Trade In Washington — Stock Surges 200% ↗

October 08, 2025

An AI stock disclosed as a new 2025 purchase by Nancy Pelosi is up over 200% since she took the position in January.

Via Benzinga

Topics Artificial Intelligence

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗

September 29, 2025

The U.S. pharmaceutical industry is at the center of a policy maelstrom.

Via Benzinga

Topics ETFs

Cathie Wood's Reshuffle Tuesday: Loads Up On AMD, Figma And Bullish, Trims Tempus AI ↗

September 16, 2025

On Tuesday, Cathie Wood-led Ark Invest executed significant trades, including buying shares of Advanced Micro Devices Inc. (NASDAQ:AMD) and Bullish Inc. (NYSE:BLSH), while selling shares o

Via Benzinga

Cathie Wood, Dan Ives Align On These 11 AI Stock Picks — Some Might Surprise You ↗

September 15, 2025

Cathie Wood and Dan Ives have 11 stocks in common across ETFs. A look at the AI stocks the two key figures are betting on.

Via Benzinga

Topics Artificial Intelligence ETFs

Cathie Wood's Ark Pivots: Sells Tempus AI After FDA Win, Loads Up On Amazon, Figma And This Trendy Crypto Stock ↗

September 11, 2025

Cathie Wood-led Ark Invest sold shares of Tempus AI, bought Bullish, Amazon, and Figma. The moves align with recent achievements and advancements of the companies.

Via Benzinga

Topics Artificial Intelligence

Cathie Wood's Ark Dumps $2.1 Million Of This Hot AI Stock Despite Recent Acquisition Boost ↗

September 09, 2025

On Tuesday, Cathie Wood-led Ark Invest sold shares of Tempus AI Inc (NASDAQ: TEM) through ARK Genomic Revolution ETF (ARKG) and ARK Innovation ETF (ARKK) totaling $2.1 million. This follows Tempus AI's...

Via Benzinga

Topics Artificial Intelligence ETFs

Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers ↗

August 25, 2025

Hims & Hers investors hit with more bad news as Novo Nordisk partners with GoodRx to offer discounted access to competing products. ETFs with high concentration in HIMS may face risks and losses.

Via Benzinga

Topics ETFs

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.